Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03416231|
Recruitment Status : Unknown
Verified January 2018 by Afﬁliated Hospital of North Sichuan Medical College.
Recruitment status was: Recruiting
First Posted : January 31, 2018
Last Update Posted : January 31, 2018
|Condition or disease||Intervention/treatment||Phase|
|NSCLC||Drug: Apatinib Drug: Docetaxel||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Study of Combined Treatment of Apatinib With Docetaxel as Post Second-line Therapy in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC)|
|Actual Study Start Date :||November 30, 2016|
|Estimated Primary Completion Date :||January 1, 2019|
|Estimated Study Completion Date :||January 1, 2020|
Experimental: apatinib plus docetaxel
apatinib combine with docetaxel， 4~6 cycles
apatinib, at a dose of 250 mg daily,Treatment was continued until disease progression.
Other Name: Aitan
Docetaxel, at a dose of 75mg/m2 on days 1 and 22, repeat every 4 weeks for 4~6 cycles.
- objective response rate (ORR) [ Time Frame: 6 month ]Proportion of patients with reduction in tumor burden of a predefined amount
- progression free survival (PFS) [ Time Frame: 12 month ]The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse.
- disease control rate (DCR) [ Time Frame: 6 month ]Disease Control Rate (DCR) and Clinical Benefit Rate (CBR) are defined as the percentage of patients with advanced or metastatic cancer who have achieved complete response, partial response and stable disease to a therapeutic intervention in clinical trials of anticancer agents.
- 6-month overall survival rate [ Time Frame: 6 month ]6-month overall survival rate
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03416231
|Contact: Daiyuan Ma, M.Dfirstname.lastname@example.org|
|Affiliated Hospital of North Sichuan Medical College||Recruiting|
|Nanchong, Sichuan, China, 600000|
|Contact: Daiyuan Ma, M.D 868172246171 email@example.com|
|Principal Investigator: xin hu, M.D|
|Principal Investigator: xiangdong fang, M.D|
|Principal Investigator:||Daiyuan Ma, M.D||Afﬁliated Hospital of North Sichuan Medical College|
|Study Director:||xin hu, M.D.||Nanchong Central Hospital|
|Study Director:||xiangdong fang, M.d.||Dazhou Central Hospital|